Pneumocystis jirovecii

Below is your **complete, concise-but-exhaustive medical note on *Pneumocystis jirovecii* (PCP) pneumonia**, following your preferred pattern: ✔️ Definition ✔️ Pathophysiology ✔️ Risk factors ✔️ Clinical features ✔️ Investigations ✔️ Differential diagnoses ✔️ Management (stepwise) ✔️ Full drug details (indications, MoA, dosing, PK, side effects, contraindications, monitoring, counselling) ✔️ Prophylaxis --- # **PNEUMOCYSTIS JIROVECII (PCP) – COMPLETE NOTE** ## **1. DEFINITION** Pneumocystis jirovecii pneumonia (PCP) is a **severe opportunistic fungal pneumonia** caused by *P. jirovecii*, seen mainly in **HIV patients with CD4 <200**, transplant patients, long-term steroid users, and other immunocompromised states. Although fungal, PCP behaves like an **atypical interstitial pneumonia**. --- ## **2. PATHOPHYSIOLOGY** * *P. jirovecii* colonizes alveoli → multiplies in immunosuppressed hosts. * Causes **diffuse alveolar damage** and **protein-rich foamy intra-alveolar exudate**. * Leads to: * Impaired gas exchange * Severe **hypoxemia** * ↑ A–a gradient * Interstitial inflammation (predominantly plasma cells, lymphocytes). * Surfactant dysfunction → ↓ lung compliance. --- ## **3. RISK FACTORS** ### **HIV-related** * **CD4 <200 cells/µL** * High viral load * Prior PCP infection * Not on ART ### **Non-HIV** * Prolonged steroids (>20 mg/day prednisone ≥4 weeks) * Solid organ transplant * Hematologic malignancies * Chemotherapy * TNF-α inhibitor therapy * Chronic lung disease * Severe malnutrition * Post-COVID immunosuppression --- ## **4. CLINICAL FEATURES** ### **Symptoms** * **Subacute fever** * **Progressive dyspnea** (HIV: weeks; non-HIV: days) * **Dry nonproductive cough** * Pleuritic chest pain * Fatigue, weight loss ### **Signs** * Tachypnea, tachycardia * **Hypoxemia with exertion first** * Bibasal fine crackles * Cyanosis (late) ### **Severe disease marker** * **PaO₂ <70 mmHg** or **A–a gradient >35 mmHg** --- ## **5. INVESTIGATIONS** ### **1. Blood tests** * ↑ LDH (often >500 IU/L) – nonspecific but supportive * β-D-glucan positive in many cases * ABG: ↓ PaO₂, ↑ A–a gradient ### **2. Imaging** #### **Chest X-ray** * **Bilateral diffuse interstitial / ground-glass opacities** (“bat-wing” pattern) * No effusion typically #### **HRCT chest** * **Ground-glass opacities**, septal thickening (crazy-paving) ### **3. Microbiology** * Induced sputum (40–60% sensitive) * BAL (90–99% sensitive) – gold standard * Stains: silver stain, Giemsa * PCR highly sensitive * DFA staining ### **4. Special Tests** * Serum LDH high * β-D-glucan elevated --- ## **6. DIFFERENTIAL DIAGNOSES** * CMV pneumonia * Bacterial pneumonia (esp. atypical) * Viral pneumonias (COVID, influenza) * Tuberculosis * Hypersensitivity pneumonitis * ARDS * Alveolar proteinosis * Drug-induced pneumonitis (amiodarone, MTX) --- # **7. MANAGEMENT (STEPWISE)** ## **A. Assess severity** * **Mild–moderate** → PaO₂ ≥70 * **Moderate–severe** → PaO₂ <70 or A–a gradient >35 --- ## **B. First-line treatment** # **1. TMP–SMX (Co-trimoxazole)** **Indication:** First line for all severities **Mechanism of action:** * TMP: inhibits dihydrofolate reductase * SMX: inhibits dihydropteroate synthase → Combined **folate synthesis inhibition** in organism ### **Adult Dosing** * **TMP 15–20 mg/kg/day + SMX 75–100 mg/kg/day** IV or PO divided q6–8h for **21 days** (HIV) * **Non-HIV:** 14 days may be adequate ### **Pharmacokinetics** * Good lung penetration * Renal elimination * Adjust dose in renal impairment ### **Side Effects** Common: * Nausea, vomiting * Rash * Hyperkalemia * Hyponatremia * AKI * Elevated LFTs Serious: * **Stevens–Johnson syndrome (SJS)** * **Hemolysis in G6PD deficiency** * Bone marrow suppression * Aseptic meningitis ### **Contraindications** * Sulfa allergy * Severe hepatic failure * Significant marrow suppression ### **Drug interactions** * Warfarin ↑ INR * ACEI/ARBs + TMP → severe hyperkalemia * Methotrexate → marrow toxicity ### **Monitoring** * CBC * Creatinine * Electrolytes (esp. K⁺, Na⁺) * LFTs ### **Patient counselling** * Drink adequate water * Report rash immediately * Avoid OTC NSAIDs * Expect gradual improvement over days --- ## **C. Adjunctive corticosteroids** 🚨 Only in **moderate–severe PCP** (PaO₂ <70 or A–a >35) ### **Prednisone regimen:** * Day 1–5: **40 mg PO BID** * Day 6–10: **40 mg PO daily** * Day 11–21: **20 mg PO daily** OR IV methylprednisolone (75% equivalent dose) --- ## **D. Alternatives to TMP–SMX** ### **1. Pentamidine (IV)** Indication: severe PCP when TMP-SMX contraindicated MoA: inhibits DNA/RNA/protein synthesis Dose: **4 mg/kg/day IV** PK: renal excretion, accumulates in tissues Side effects: * Nephrotoxicity * Hypoglycemia → hyperglycemia * Pancreatitis * Arrhythmias * Hypotension * Electrolyte abnormalities Monitoring: glucose, renal function, ECG --- ### **2. Atovaquone (PO)** For mild–moderate PCP MoA: inhibits mitochondrial electron transport Dose: **750 mg PO BID with fatty meal** × 21 days Side effects: rash, GI upset, ↑ LFTs --- ### **3. Clindamycin + Primaquine** Indication: Mild–moderate when TMP–SMX not tolerated MoA: protein synthesis inhibition + oxidative damage Dose: * Clindamycin 600–900 mg IV TID * Primaquine 15–30 mg PO daily Side effects: * Hemolysis in G6PD deficiency * Rash * Diarrhea --- ### **4. Dapsone + TMP**, **Dapsone + Trimethoprim** Avoid in G6PD deficiency Side effects: methemoglobinemia, hemolysis --- # **8. PROPHYLAXIS (VERY IMPORTANT)** ### **Indications for primary prophylaxis** * HIV: **CD4 <200** or oropharyngeal candidiasis * Non-HIV: prolonged steroids, transplant, chemo ### **First-line prophylactic agent** ## **TMP–SMX 1 DS tablet daily OR 1 SS daily** Alternatives: * Dapsone * Atovaquone * Aerosolized pentamidine Stop prophylaxis when: * HIV: CD4 >200 for >3 months on ART --- # **9. COMPLICATIONS** * Respiratory failure * Pneumothorax (subpleural cysts rupture) * ARDS * Death if untreated --- # **10. KEY EXAM POINTS** * LDH ↑ is supportive, not diagnostic * HIV: subacute, non-HIV: severe + rapid * Steroids improve mortality when PaO₂ <70 * TMP–SMX remains the **gold standard** * Never give primaquine or dapsone without **G6PD testing** --- If you want, I can also provide: ✅ **10–30 case scenarios** ✅ **Hard MCQs (HTML + CSS + JS in one file)** ✅ **Differential diagnosis scenarios** Just tell me how many you want. Below are **25 high-yield, exam-style, real-life case scenarios of *Pneumocystis jirovecii* pneumonia (PCP)**. Each case includes: ✔ Presentation ✔ Key findings ✔ Diagnosis triggers ✔ Management steps If you want, I can also generate **hard MCQs**, **HTML/JS quiz files**, or **expanded management pathways**. --- # **📘 25 CASE SCENARIOS — PNEUMOCYSTIS JIROVECII (PCP)** --- ## **CASE 1 — Classic HIV PCP** A 32-year-old male with newly diagnosed HIV (CD4 = 84) presents with **progressive dyspnea × 3 weeks**, dry cough, fever. SpO₂ drops from 94% to 82% on minimal exertion. CXR: **Bilateral diffuse ground-glass opacities**. LDH: 560 U/L. ABG: PaO₂ 60 mmHg. **Diagnosis:** Moderate–severe PCP **Management:** IV TMP–SMX + prednisone taper. --- ## **CASE 2 — Sudden deterioration** A patient on day 4 of TMP–SMX for PCP suddenly develops acute pleuritic pain and hypoxia. CXR: **Large right pneumothorax**. **Complication:** PCP-related pneumothorax (due to subpleural cyst rupture). **Management:** Chest tube + continue PCP treatment. --- ## **CASE 3 — Non-HIV, rapid onset** A 60-year-old man on **prednisone 40 mg/day for 2 months** (interstitial lung disease) develops acute dyspnea × 3 days. Very hypoxic. CXR: diffuse interstitial infiltrates. **Diagnosis:** Non-HIV PCP **Management:** IV TMP–SMX; early steroids (PaO₂ <70). --- ## **CASE 4 — HIV patient on ART default** A 28-year-old defaulted ART for 1 year. Now presents with weight loss + fever + cough. CD4 = 36. β-D-glucan positive. **Diagnosis:** PCP **Management:** TMP–SMX; start ART after **2 weeks** (to avoid IRIS). --- ## **CASE 5 — Prophylaxis failure** A 44-year-old HIV patient on **dapsone prophylaxis** develops PCP. G6PD was never checked. **Diagnosis:** Breakthrough PCP (dapsone failure due to improper absorption or resistance). **Management:** Switch to TMP–SMX; check G6PD. --- ## **CASE 6 — Transplant patient** A kidney-transplant recipient on tacrolimus + prednisone presents with progressive dyspnea, dry cough, fever. CT: **ground-glass infiltrates**. **Diagnosis:** PCP in transplant recipient **Management:** IV TMP–SMX + careful renal dosing + steroids. --- ## **CASE 7 — Cancer chemotherapy** A 52-year-old woman receiving rituximab for lymphoma presents with fever, tachypnea, dry cough × 5 days. HRCT: diffuse GGO; LDH elevated. BAL PCR positive. **Management:** TMP–SMX + prednisone. --- ## **CASE 8 — Post-COVID immune suppression** A man received high-dose steroids for COVID ARDS. Now, 6 weeks later: fever, breathlessness. CT: ground-glass infiltrates. **Diagnosis:** Steroid-induced PCP **Management:** TMP–SMX ± steroids. --- ## **CASE 9 — Mild PCP** A 33-year-old HIV+ woman, CD4 = 170, has mild dry cough and fever. PaO₂ = 76 mmHg. **Management:** Oral TMP–SMX (mild); no steroids. --- ## **CASE 10 — Severe PCP with respiratory failure** HIV+ man arrives in ED with RR 40/min, cyanosis. PaO₂ = 48 mmHg. **Diagnosis:** Severe PCP **Management:** ICU care + IV TMP–SMX + IV methylprednisolone. --- ## **CASE 11 — Patient allergic to sulfa** HIV+ woman with known SJS to sulfa drugs presents with PCP. **Management:** * Clindamycin + primaquine * Or IV pentamidine if severe * Test G6PD before primaquine. --- ## **CASE 12 — PCP in poorly nourished patient** A 50-year-old alcoholic with severe malnutrition develops dyspnea × 10 days. BAL positive. **Management:** TMP–SMX; screen for electrolyte disturbances. --- ## **CASE 13 — β-D-glucan positive but CXR normal** Early PCP: LDH high, β-D-glucan positive, but normal X-ray. HRCT shows patchy ground-glass changes. **Diagnosis:** Early PCP **Management:** TMP–SMX. --- ## **CASE 14 — PCP in pregnancy** HIV+ pregnant woman with CD4 = 90 presents with worsening breathlessness. CT avoided; X-ray shows diffuse infiltrates. **Management:** TMP–SMX (benefits outweigh risks); steroids if indicated; folinic acid. --- ## **CASE 15 — Relapse after stopping prophylaxis early** HIV patient stopped TMP–SMX prophylaxis when CD4 became 210 for only 6 weeks. Now presents with PCP. **Cause:** Prophylaxis was stopped too early. **Management:** Full treatment + restart prophylaxis until CD4 >200 for **≥3 months**. --- ## **CASE 16 — Hyperkalemia due to therapy** A patient on high-dose TMP–SMX for PCP develops K⁺ = 6.1. **Cause:** TMP inhibits renal potassium excretion. **Management:** Treat hyperkalemia; adjust TMP–SMX dose. --- ## **CASE 17 — AKI during therapy** Creatinine rises to 2.4 mg/dL on TMP–SMX. **Management:** * Dose adjust * Monitor electrolytes * Ensure hydration * Consider alternative if worsening. --- ## **CASE 18 — PCP vs CMV pneumonia confusion** Transplant patient has fever and diffuse infiltrates. PCP stains negative; CMV PCR very high. **Diagnosis:** CMV pneumonia (PCP mimic). **Management:** Ganciclovir. --- ## **CASE 19 — PCP in patient on TNF-α inhibitor** A patient on infliximab for rheumatoid arthritis develops fever, progressive breathlessness. CT: interstitial GGO. **Diagnosis:** Immunosuppression-related PCP **Management:** TMP–SMX. --- ## **CASE 20 — PCP with severe hyponatremia** A patient develops Na = 121 due to TMP–SMX + SIADH-like effect. **Management:** Correct sodium + continue treatment with caution. --- ## **CASE 21 — PCP + Pneumothorax + ARDS overlap** Severely ill PCP patient on ventilator suddenly has worsening hypoxia. CXR: bilateral infiltrates + small pneumothorax. **Management:** * Ventilation with low tidal volume * Chest tube if needed * Continue PCP therapy. --- ## **CASE 22 — PCP in untreated HIV found incidentally** A homeless patient with chronic cough is brought in. CXR done for TB screening shows diffuse opacities. BAL reveals PCP. **Management:** TMP–SMX + ART initiation after 2 weeks. --- ## **CASE 23 — PCP in obesity-hypoventilation syndrome** Obese immunosuppressed patient presents with confusion and dyspnea. ABG: Severe hypoxemia + hypercapnia. **Management:** * NIV/CPAP * TMP–SMX * Steroids * Slow oxygen escalation to avoid CO₂ retention. --- ## **CASE 24 — PCP in patient with hematologic malignancy** AML patient receiving chemotherapy becomes febrile and dyspneic. CT: diffuse bilateral GGO. BAL PCR: positive for *P. jirovecii*. **Management:** IV TMP–SMX; consider pentamidine if neutropenia. --- ## **CASE 25 — PCP diagnosed only on HRCT** CXR normal. HRCT: classic ground-glass with septal thickening (“crazy-paving”). BAL unavailable. **Diagnosis:** Radiologic PCP **Management:** TMP–SMX. --- If you want, I can now create: ✅ **20–30 Hard MCQs** ✅ **HTML + CSS + JS interactive quiz file** ✅ **Differential diagnosis case bundle** Just tell me how many.